That’s actually a valid question since many are unaware of the “nature” of this deal…
The “nature” was publicly announced: The nature of the deal is that NWBO licensed another novel patent-fortified dendritic cell platform technology from Roswell that provides NWBO with the rights to produce and commercialize the drug (if the platform continues in clinical development to reach regulatory approval). The Roswell deal mirrors the commercial rights that NWBO owns with regard to the UCLA technology (DCVax-L)…
Currently, both novel platform technologies owned by NWBO are in combo trials at UCLA and at Roswell Park. The combo trials include Merck’s pembrolizumab, the studies have progressed beyond the initial stages of PII, interim efficacy data are beginning to emerge, and the three combo studies are supported by continuing peer-reviewed grants awarded by the U.S. NIH and the U.S. DoD.
Market Data 
Markets 
AI
